Literature DB >> 25318967

Characteristics of pleural effusions in systemic lupus erythematosus: differential diagnosis of lupus pleuritis.

B Y Choi1, M J Yoon1, K Shin2, Y J Lee3, Y W Song4.   

Abstract

We investigated the clinical characteristics of pleural effusion in systemic lupus erythematosus (SLE). A prospective analysis of 17 SLE patients with pleural effusion (seven lupus pleuritis, eight transudative effusions and two parapneumonic effusions) was performed. Thirty non-SLE patients with pleural effusion were recruited as controls. A pleural fluid ANA titer ≥1:160 was found in 8/17 (47.1%) SLE patients and none of the 30 non-SLE patients (p = 0.0001). Pleural fluid to serum C3 ratios were significantly lower in SLE than in non-SLE (median (minimum-maximum) 0.29 (0.03-0.43) versus 0.52 (0.26-0.73), p = 0.0002). Among SLE patients, pleural fluid ANA titers ≥1:160 were more frequently found in patients with lupus pleuritis than in those with pleural effusion from causes other than lupus itself (85.7% versus 20.0%, p = 0.0152). Serum CRP levels were significantly increased in patients with lupus pleuritis compared with SLE patients with transudative pleural effusion (2.30 (0.30-5.66) versus 0.7 (0.12-1.47) mg/dl, p = 0.0062). In conclusion, pleural fluid ANA titer and serum CRP levels are significantly increased in lupus pleuritis.
© The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  C-reactive protein; Systemic lupus erythematosus; anti-nuclear antibody; complement; lupus pleuritis; pleural effusion

Mesh:

Year:  2014        PMID: 25318967     DOI: 10.1177/0961203314555171

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  Adalimumab-induced lupus serositis.

Authors:  Dearbhla Kelly; Oisin O'Connell; Michael Henry
Journal:  BMJ Case Rep       Date:  2015-03-04

Review 2.  Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management.

Authors:  Elena De Zorzi; Paolo Spagnolo; Elisabetta Cocconcelli; Elisabetta Balestro; Luca Iaccarino; Mariele Gatto; Francesco Benvenuti; Nicol Bernardinello; Andrea Doria; Toby M Maher; Elisabetta Zanatta
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-18       Impact factor: 10.817

3.  Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous.

Authors:  Vanessa Ocampo; Derek Haaland; K Legault; Shika Mittoo; Emily Aitken
Journal:  BMJ Case Rep       Date:  2016-08-08

Review 4.  The dynamic evolution of rheumatology in Korea.

Authors:  Ho-Youn Kim; Yeong-Wook Song
Journal:  Nat Rev Rheumatol       Date:  2015-12-17       Impact factor: 20.543

5.  A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion.

Authors:  Liyan Lin; Shuguang Li; Qiao Xiong; Hui Wang
Journal:  BMC Pulm Med       Date:  2021-03-19       Impact factor: 3.317

6.  Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus.

Authors:  Ting Zhang; Yong Du; Qingqing Wu; Hao Li; Thao Nguyen; Gabriel Gidley; Valeria Duran; Daniel Goldman; Michelle Petri; Chandra Mohan
Journal:  Arthritis Res Ther       Date:  2022-01-03       Impact factor: 5.156

7.  ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies.

Authors:  Der-Yuan Chen; Yen-Hsiang Huang; Yi-Ming Chen; Jeremy J W Chen; Tsung-Ying Yang; Gee-Chen Chang; Kuo-Tung Tang
Journal:  Lupus Sci Med       Date:  2021-11

Review 8.  Respiratory Manifestations in Systemic Lupus Erythematosus.

Authors:  Salvatore Di Bartolomeo; Alessia Alunno; Francesco Carubbi
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.